NurExone Biologic Inc. Reports Q2 2024 Financial Results
NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90), an innovative biopharmaceutical company focused on regenerative medicine therapies, has published its financial results and corporate updates for the three and six months ending June 30, 2024. This report highlights the company's financial performance and key operational advancements.
Key Business Highlights
In April, NurExone signed a contract research organization services agreement with Vivox Ltd. This agreement facilitates animal experiments as part of the preclinical testing necessary for submitting an investigational new drug (IND) application to the FDA. The goal is to evaluate the safety and efficacy of the ExoPTEN drug before commencing clinical trials with human participants, which are anticipated to start in 2025. This agreement follows a pre-IND meeting with the FDA concerning ExoPTEN, NurExone's inaugural ExoTherapy product.
On April 25, 2024, the Company's common shares began trading on the Pink Sheets platform managed by OTC Markets Group Inc. under the symbol "NRXBF". Following this, on May 6, 2024, the Company successfully uplisted to the OTCQB Venture Market, retaining the same symbol and marking a significant achievement in increasing its visibility within the financial community, particularly in the United States. Additionally, NurExone obtained Depository Trust Company (DTC) eligibility, enhancing the trading efficiency and liquidity of its shares for investors.
On June 11, 2024, NurExone announced an expansion of its ExoPTEN patent coverage, with a patent application allowance in Japan, thus broadening the Company's potential market reach.
In line with its strategic goals, NurExone entered into an amending agreement with BullVestor Medien GmBH on June 11, 2024, extending investor relations services until May 15, 2025. Furthermore, a consulting agreement with Dr. Yona Geffen, signed on June 21, 2024, brings valuable expertise to the Company’s preclinical and clinical initiatives, enhancing operational efficiency.
Growth Outlook for 2024
Dr. Lior Shaltiel, Chief Executive Officer, noted that NurExone is making significant strides in regulatory processes, including the successful transfer of essential manufacturing operations to a facility compliant with good manufacturing practices. This step is crucial for the upcoming clinical trials and commercial production. With the guidance of Dr. Yona Geffen, who has over twenty years of experience in clinical and drug development, the Company is well-prepared for ongoing growth.
In partnership with the Goldschleger Eye Institute at Sheba Medical Center, NurExone is investigating ExoPTEN's potential in the lucrative glaucoma market, with promising preliminary results reported.
Second Quarter Fiscal 2024 Financial Results
The financial performance for the second quarter of 2024 reveals several notable metrics:
- Research and development expenses net totaled US$0.51 million, up from US$0.46 million in Q2 2023, primarily due to increased costs for subcontractors and materials.
- General and administrative expenses rose to US$0.81 million from US$0.60 million in the previous year, largely driven by higher costs for professional and legal services.
- Finance expenses were recorded at US$0.01 million, a decline from income of US$0.02 million during the same period last year.
- The overall net loss for the quarter amounted to US$1.33 million, compared to a loss of US$1.04 million in Q2 2023.
As of June 30, 2024, cash and cash equivalents reached US$2.39 million, a significant rise from US$0.54 million at the end of 2023. Working capital improved to US$2.24 million from US$0.07 million, primarily driven by a successful private placement in January 2024 and warrant exercises in March 2024. However, these inflows were partially offset by operational cash outflows totaling US$2.57 million.
By June 30, 2024, NurExone reported an accumulated deficit of US$16.30 million, up from US$14.06 million as of December 31, 2023.
Eran Ovadya, Chief Financial Officer, highlighted the Company’s ongoing dedication to advancing research and development efforts while preparing ExoPTEN for clinical trials and commercial manufacturing.
About NurExone Biologic Inc.
NurExone Biologic Inc. is listed on the TSX Venture Exchange and is focused on developing innovative, biologically-guided exosome-based therapies for non-invasive delivery to patients with Central Nervous System injuries. The Company’s flagship product, ExoPTEN, has demonstrated the ability to restore motor function in a significant percentage of laboratory rats and has received Orphan Drug Designation from the FDA.
For more information, interested parties can reach out to Dr. Lior Shaltiel, Chief Executive Officer, at +972-52-4803034; or via email at info@nurexone.com.
Frequently Asked Questions
What are NurExone's recent key achievements?
NurExone has successfully entered into crucial agreements for preclinical testing, expanded its patent coverage, and achieved uplisting to the OTCQB Venture Market.
How has NurExone's financial situation changed?
As of June 30, 2024, NurExone's cash reserves have significantly increased, indicating improved working capital and reduced operational cash outflows despite reporting net losses.
What is ExoPTEN?
ExoPTEN is NurExone's proprietary product designed for treating spinal cord injuries, which has shown promising efficacy in preclinical studies.
Who is leading NurExone's clinical development efforts?
Dr. Yona Geffen is consulting for NurExone, bringing extensive expertise in biotechnology and clinical development.
Where can I find more information about NurExone Biologic Inc.?
For comprehensive details, please visit NurExone's official website or reach out to their investor relations team.
